Autologous peripheral blood-derived CD34+ cells
- Generic Name
- Autologous peripheral blood-derived CD34+ cells
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Autologous peripheral blood-derived CD34+ cells, or CLBS119 (a proprietary version being developed by Caladrius Biosciences, Inc.), are hematopoietic stem cells. It is also a cell therapy being investigated by Caladrius Biosciences in the clinical trial NCT04522817 (CLBS119 for Repair of COVID-19 Induced Pulmonary Damage).
- Associated Conditions
- -
- Associated Therapies
- -
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Lisata Therapeutics, Inc.
- Registration Number
- NCT04522817
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: BCNUDrug: EtoposideDrug: FilgrastimDrug: Antithymocyte globulinDrug: CyclosporineDrug: Mycophenolate mofetilDrug: RituximabProcedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)Procedure: Total lymphoid irradiationDrug: CD34+ CellsDrug: Solu-Medrol
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 50
- Registration Number
- NCT00481832
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath